Vinoxin MV (vincamine) tablets with prolonged release 30 mg. №20

Description

Vinoxin MV (vincamine) tablets with prolonged release 30 mg. №20

Composition

active substance: vincamine;
1 tablet contains vincamine 30 mg;
excipients: lactose monohydrate; hypromellose; copovidone; colloidal hydrophobic silicon dioxide; colloidal aqueous silicon dioxide; magnesium stearate.

Dosage form

Prolonged-release tablets.
Basic physical and chemical properties: round tablets, flat-cylindrical, chamfered, white or almost white.
Pharmacotherapeutic group

Peripheral vasodilators.

ATX code C04A X07.

Pharmacological properties

Vincamine has a selective vasoregulatory effect on cerebral circulation, helping to adapt cerebral circulation to the metabolic needs of the brain. The drug improves brain metabolism by increasing the oxidation of glucose, thereby increasing energy production and helping to increase the overall activity of the body. Vincamine increases the oxygen supply to neurons in a state of hypoxia. The drug reduces and stabilizes peripheral vascular resistance of the brain. Vincamine has been shown to have no biological, hematological toxicity or side effects on the kidneys or liver.

Indication

To normalize and adapt cerebral circulation to the metabolic needs of the brain: to improve, regulate and maintain brain function in the following conditions:

• memory impairment;
• impaired concentration;
• diabetic angiopathy;
• atherosclerotic lesions of the vessels of the brain;
• post-traumatic craniocerebral disorders;
• after acute cerebrovascular accident;
• cerebral disorders after cerebral ischemia;
• hypertensive encephalopathy;
• hearing and vision disorders of vascular origin;
• disorientation in space and time, emotional disorders that are the result of various mental disorders.

Contraindication

Hypersensitivity to any component of the drug Vinoxin MV. Brain tumors (or diseases that cause increased intracranial pressure), convulsive disorders, acute stroke, cardiac arrhythmias, severe electrolyte disturbances (hypokalemia or hypocalcemia).
Interaction with other medicinal products and other forms of interaction
Concomitant use with drugs that may provoke torsade des pointes should be avoided. If this is not possible, careful clinical and ECG monitoring is recommended.
Interactions characteristic of vinca alkaloid.
Quinupristine and dalfopristin are potent inhibitors of cytochrome P450 3A4 and may increase the concentration of vinca alkaloid when co-administered. Patients should be monitored for adverse symptoms of vinca alkaloid and the dose of vincamin should be adjusted accordingly.
A possible mechanism of interaction between itraconazole and vinca alkaloid is inhibition of cytochrome P450 by itraconazole. Itraconazole may also inhibit the P-glycoprotein pump, which is responsible for the excretion of vinca alkaloid. Therefore, patients should be closely monitored when itraconazole and vincamine are co-administered.

Use during pregnancy or breastfeeding

Contraindicated.

Method of application and dosage

Adults should be prescribed 1 tablet orally 2 times a day. The duration of treatment is determined by the doctor individually depending on the course of the disease.

Children

Vinoxin MV tablets are not recommended for use in children.

Overdose

In case of overdose, careful clinical monitoring, ECG monitoring, symptomatic treatment and maintenance of vital functions are recommended. There is no specific antidote.

Side effects:

• Mental disorders: a slight increase in mental activity;
• From the nervous system: headache, dizziness;
• From the cardiovascular system: prolongation of the QT interval, ventricular fibrillation (torsade des pointes);
• From the digestive system: nausea, heartburn, diarrhea, constipation, dry mouth;
• From the immune system: hypersensitivity reactions, including angioneurotic edema;
• From the skin and subcutaneous tissue: erythema, itching, allergic dermatitis, urticaria, papular rash.